A discovery pipeline for identification and in vivo validation of drugs that alter T cell/ dendritic cell interaction

The interaction between T cells and dendritic cells (DC) is central to determining whether or not an adaptive immune response develops. Autoimmune diseases like rheumatoid arthritis result from inappropriate activation of self-antigen specific T cells, therefore targeting the interaction between T cells and DCs is of considerable therapeutic interest. Here, we describe the development and validation of a drug development platform that includes a high-throughput image-based screening assay and a complementary in vivo model. The in vitro assay directly measures the ability of compounds to influence the interaction of T cells with DC, both negatively and positively. While the in vivo model allows the validation of hit molecules directly in the lymph nodes of intact animals. Using this pipeline, we identify a new function for the protein kinase inhibitor AS703569 by inhibiting T cell/ DC interactions in vitro and in vivo. ### Competing Interest Statement Emma Evertsson and Stephen Delany are employees of AstraZeneca